State Farm Mutual Automobile Insurance Co. Reduces Johnson & Johnson Stake

Institutional investor cuts holdings in pharmaceutical giant by 0.3% in Q3 2026

Mar. 3, 2026 at 7:55am

State Farm Mutual Automobile Insurance Co., a major institutional investor, reduced its stake in Johnson & Johnson (NYSE: JNJ) by 0.3% during the third quarter of 2026, according to a recent 13F filing with the Securities and Exchange Commission. The insurance company still holds a significant position in J&J, owning approximately 1.31% of the company's outstanding shares valued at over $5.8 billion.

Why it matters

As one of the largest institutional investors in Johnson & Johnson, changes in State Farm's holdings can provide insight into broader market sentiment around the pharmaceutical company. The modest reduction in stake suggests State Farm may have reallocated capital to other investment opportunities, though the insurance firm still maintains a sizable position in J&J.

The details

In its 13F filing, State Farm reported owning 31,590,952 shares of Johnson & Johnson as of the end of the third quarter of 2026. This represents a 0.3% decrease from the 31,675,492 shares the firm held in the prior quarter. Despite the reduction, Johnson & Johnson remains one of State Farm's top holdings, accounting for approximately 4.9% of the insurance company's total investment portfolio.

  • State Farm Mutual Automobile Insurance Co. filed its 13F report for the third quarter of 2026 on March 3, 2026.

The players

State Farm Mutual Automobile Insurance Co.

A major U.S. insurance company that is one of the largest institutional investors in Johnson & Johnson.

Johnson & Johnson

A multinational pharmaceutical and medical devices company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

The modest reduction in State Farm's Johnson & Johnson holdings suggests the insurance firm may be diversifying its portfolio, though it still maintains a sizable stake in the pharmaceutical giant. Investors will likely continue to monitor institutional ownership changes for insights into broader market sentiment around Johnson & Johnson.